Iovance Biotherapeutics IOVA 深 沪
已收盘 07-02 16:00:00 美东时间
4.31
+0.340
+8.56%
华盛通- 最 高4.32
- 今 开4.07
- 成交量 2054.20万股
- 最 低 3.89
- 昨 收 3.97
- 总市值 19.24亿
- 52周最高 5.63
- 市盈率 静 --
- 换手率 4.60%
- 52周最低 1.70
- 委 比 -51.88%
- 总股本 4.47亿
- 历史最高 54.208
- 量 比 1.37
- 振 幅 10.83%
- 历史最低 1.6385
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多财报速睇 | Iovance Biotherapeutics 2026财年Q2营收0.87亿美元，同比增长45.0%；归母净利润亏损1.15亿美元，同比亏损扩大15.0%
华盛资讯7月3日讯，Iovance Biotherapeutics公布2026财年Q2业绩，公司Q2营收0.87亿美元，同比增长45.0%，归母净利润亏损1.15亿美元，同比亏损扩大15.0%。
今天 05:34
Iovance updates outlook, highlighting Amtagvi growth and pipeline
An update from Iovance Biotherapeutics ( ($IOVA) ) is now available. On June 30...
今天 05:32
安进对阵Iovance Biotherapeutics 2026年哪只医疗股更值得买入
本次对比聚焦两只美股医疗标的：成熟药企安进（AMGN）与专注肿瘤浸润淋巴细胞疗法的新锐生物科技企业Iovance生物治疗（IOVA），分析二者2026年的投资价...
06-24 08:20
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics granted 140,860 inducement stock options to 27 new, non-executive employees on June 18, 2026, under its 2021 Inducement Plan. The options have an exercise price of $3.91, vesting over three years with one-third vesting on the first anniversary of the employee’s start date and the remainder vesting in eight quarterly installments over the next two years. Iovance focuses on developing polyclonal tumor infiltrating lymphocyte...
06-19 21:15
Iovance Biotherapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
https://www.sec.gov/Archives/edgar/data/1425205/000110465926075778/iova-20260618xs3asr.htm
06-19 04:33
Iovance rises as Australia approves melanoma therapy Amtagvi
Shares of Iovance Biotherapeutics (IOVA) climbed on Thursday after the Therapeutic Goods Administration of Australia granted conditional approval for the company’s cell therapy, Amtagvi, as a late-lin...
06-05 00:27
Iovance Biotherapeutics Announces Allowance To Proceed From FDA For Investigational New Drug Application For Phase 1/2 Basket Study Of IOV-5001
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer,
06-01 19:41
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics granted stock options for 93,340 shares to 13 new, non-executive employees on May 21, 2026, under its 2021 Inducement Plan. Each option has an exercise price of $3.70 and vests over three years. The company specializes in developing TIL therapies for cancer patients, with Amtagvi® as the first FDA-approved T cell therapy for solid tumors. Forward-looking statements are included, and risks are outlined in SEC filings. Conta...
05-22 21:15
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Iovance Biotherapeutics Signals Strong Momentum in Call
Iovance Biotherapeutics (($IOVA)) has held its Q1 earnings call. Read on for th...
05-09 09:28
